Key result
Immunosuppression achieves similar resolution of inflammatory infiltrates in B19V-positive and virus-negative patients.
Why the study?
Whether immunosuppressive treatment benefits patients with inflammatory cardiomyopathy and parvovirus B19 persistence, which does not represent active infection, is uncertain.
Does a 6-month course of prednisolone and azathioprine improve LVEF and reduce inflammation similarly in B19V-positive and virus-negative patients with inflammatory cardiomyopathy?
Observational (n=68)
No
Does a 6-month course of prednisolone and azathioprine improve LVEF and reduce inflammation similarly in B19V-positive and virus-negative patients with inflammatory cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Immunosuppressive treatment with prednisolone and azathioprine safely improves LVEF and resolves inflammation in inflammatory cardiomyopathy patients with B19V persistence, yielding similar benefits to virus-negative patients.
Parvovirus B19 (B19V) infection is acquired in childhood and persists lifelong in approximately 70% of healthy adults and may belong to a cardiac bioportfolio without clinical significance.1 However, B19V DNA is also found in the majority of chronic inflammatory cardiomyopathy patients with low copy numbers, questioning whether this finding contributes to the disease and influences treatment implications.2-4 Current European Society of Cardiology and American Heart Association recommendations support an anti-inflammatory treatment regime in inflammatory cardiomyopathy patients when active cardiac infection is excluded.5 Whether this precaution holds true for patients with B19V persistence, which does not principally represents an active infection, is under discussion.4 To gain insights into immunosuppressive treatment effects of B19V-negative and -positive patients with endomyocardial biopsy (EMB)-proven inflammatory cardiomyopathy, we compared the changes in systolic left ventricular ejection fraction (LVEF, %), B19V viral genome copy numbers (B19V DNA2) and grade of inflammation of 51 consecutive B19V-positive patients [33 men (65%), mean age 45.1 ± 14.8 years, 9 (11.6%) with > 500 DNA copies/μg DNA] and 17 virus-negative patients with inflammatory cardiomyopathy [12 men (70.6%), mean age 45.6 ± 13.9 years] during a 6-month course with prednisolone and azathioprine regimen in addition to standard heart failure medication in a single-centre observational investigation. Patient characteristics before and after treatment are displayed in the online supplementary Table S1. Six months after treatment, inflammatory infiltrates had resolved in 12 (70.5%) virus-negative (P < 0.0001) and 34 (66%) B19V DNA-positive patients (P < 0.0001) (Figure 1C and 1D). B19V copy number did not significantly change (Figure 1E). LVEF of both groups improved similarly upon treatment (Figure 1A and 1B). This result was also seen in 8 patients who showed in addition a transcriptional activity at baseline (viral mRNA VP1/VP23) (Figure 1A). Neither viral copy number nor transcriptional activity correlated with the LVEF response. EMB material from 22 patients allowed extra experimental insights demonstrating the down-regulation of the innate immune mediators nucleotide-binding oligomerization domain 2 (NOD2), caspase 1 and interleukin-1β (online supplementary Figure S1) following the course of treatment, suggesting that the treatment reduced inflammatory, apoptotic, and pyroptotic signalling, independent of B19V persistence. An extended observation (mean 13 months after treatment) of 35 available patients showed a stable LVEF improvement in both groups. We conclude that patients with inflammatory cardiomyopathy and B19V persistence without signs of systemic active infection may gain a similar long lasting and safe benefit from immunosuppressive treatment, as do viral negative individuals. These results need further verification in a randomized controlled trial. We thank Mrs. Monika Willner and Mrs. Anika Koschel for excellent assistance. We are thankful for the grant to CT for the CaPACITY programme (Cortisone in PArvovirus inflammatory CardIomyopaThY) of the BCRT sponsored by the Federal Ministry of Education and Research (BMBF), Germany. We are thankful to the members and co-workers of the ‘Institut Kardiale Diagnostik und Therapie’ (IKDT, CEO: Prof. Heinz-Peter Schultheiss), who did the biopsy routine analyses. Conflict of interest: none declared. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Tschöpe et al. (2019) conducted an observational in Inflammatory cardiomyopathy (n=68). Parvovirus B19 (B19V) positive status vs. Virus-negative status was evaluated on Resolution of inflammatory infiltrates. Immunosuppressive treatment with prednisolone and azathioprine led to similar resolution of inflammatory infiltrates in B19V-positive and virus-negative patients.
Synapse has enriched 10 related papers. Consider them for comparative context: